{
  "id": 20321625,
  "title": "CAR T-cell therapy shows promise for patients with lupus",
  "url": "https://urgent.news/2026/11/16/car-t-cell-therapy-shows-promise-for-patients-with-lupus",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-16T20:00:03.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-car-cell-therapy-patients-lupus.html"
  },
  "original_language": "en",
  "account": "A study presented at the ACR Convergence 2026 conference suggests that chimeric antigen receptor T-cell (CAR T-cell) therapy may be beneficial for patients with systemic lupus erythematosus (SLE). Researchers from Boston University Medical Center analyzed data from 31 clinical studies involving 243 participants who had refractory SLE and had failed two or more immunosuppressants. The findings showed that CAR T-cell therapy led to consistent reductions in disease activity, with a mean SLE disease activity index (SLEDAI) dropping from 13.0 at the start of treatment to 2.2 after six months.\n\nHowever, the therapy did have some adverse effects. Five percent of patients experienced immune effector cell-associated neurotoxicity syndrome, while 5% developed severe infections. Additionally, 9% of patients experienced prolonged hematologic toxicity. The study found that autologous therapies, which use the patient's own cells, were associated with a steeper decline in SLEDAI compared to allogeneic therapies and were more likely to result in achieving an SLEDAI score of 0 at the end of treatment. This suggests that autologous CAR T-cell therapy may be a promising option for patients with SLE, particularly those with lupus nephritis.",
  "summary": "For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence 2026), held from Nov. 6 to 11 in Orlando, Florida.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}